Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 6Phase EARLY_PHASE1 2

Status

Completed 6

Sponsor Class

OTHER 5NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6Other hematologic neoplasm 1Myeloid 1Genitourinary 1Classical hematology 1

Conditions

Pancreatic Neoplasms 4Resectable Pancreatic Cancer 1Advanced Pancreatic Cancer 1Adenocarcinoma 1

Interventions

Oxaliplatin 778Fluorouracil 637Capecitabine 573Gemcitabine 478Leucovorin 458Irinotecan 444Bevacizumab 443Cisplatin 337Radiotherapy 282Cetuximab 251Paclitaxel 180S 1 (combination) 175pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 130apatinib 130130-nm albumin-bound paclitaxel 127Folfox protocol 120durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106Surgical Procedures, Operative 102regorafenib 101Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × paricalcitol × Gastrointestinal × Clear all
NCT03415854 2026-05-12

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed
34 enrolled 11 charts
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT03138720 2026-04-22

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

HonorHealth Research Institute

Phase 2 Completed
40 enrolled 22 charts
Gastrointestinal

Resectable Pancreatic Cancer

NCT04524702 2026-01-23

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Emory University

Phase 2 Completed
10 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

NCT04054362 2025-11-21

PINBALL

Barts & The London NHS Trust

Phase 2 Completed
27 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04617067 2024-03-06

Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer

Cancer Trials Ireland

Phase 2 Completed
15 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

NCT03331562 2022-12-27

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Translational Genomics Research Institute

Phase 2 Completed
24 enrolled 14 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡